D. Kellar

发表

Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery

Barry A. Bunin, C. Talcott, M. Sarker, 2015, PLoS neglected tropical diseases.

Lead Identification to Clinical Candidate Selection

F. Supek, J. Gut, A. Renslo, 2015, Journal of biomolecular screening.

Myeloid expression of the AP‐1 transcription factor JUNB modulates outcomes of type 1 and type 2 parasitic infections

E. Huang, D. Herbert, D. Kellar, 2015, Parasite immunology.

Diversity-oriented synthesis yields a new drug lead for treatment of chagas disease.

Jeremy R. Duvall, S. Schreiber, Ana Rodriguez, 2014, ACS medicinal chemistry letters.

Synthesis of a Sugar-Based Thiosemicarbazone Series and Structure-Activity Relationship versus the Parasite Cysteine Proteases Rhodesain, Cruzain, and Schistosoma mansoni Cathepsin B1

R. J. Alves, Brian M. Suzuki, R. S. Ferreira, 2015, Antimicrobial Agents and Chemotherapy.

4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency

J. Gut, J. McKerrow, M. Cameron, 2014, Journal of medicinal chemistry.

Targeting Ergosterol Biosynthesis in Leishmania donovani: Essentiality of Sterol 14alpha-demethylase

J. McKerrow, G. De Muylder, W. Roush, 2015, PLoS neglected tropical diseases.

Binding Mode and Potency of N-Indolyloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51

J. Gut, J. McKerrow, M. Cameron, 2014, Journal of medicinal chemistry.

Binding Mode and Potency of N-Indolyloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51

J. Gut, J. McKerrow, M. Cameron, 2014, Journal of Medicinal Chemistry.